Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0TS6S
|
|||
Former ID |
DNC002262
|
|||
Drug Name |
ISIS 103622
|
|||
Drug Type |
Antisense drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Company |
Isis Pharmaceuticals
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | WWP1 messenger RNA (WWP1 mRNA) | Target Info | . | [1] |
KEGG Pathway | Ubiquitin mediated proteolysis | |||
Endocytosis | ||||
Panther Pathway | Ubiquitin proteasome pathway | |||
Pathway Interaction Database | ErbB4 signaling events | |||
Validated transcriptional targets of deltaNp63 isoforms | ||||
Validated transcriptional targets of TAp63 isoforms | ||||
TGF-beta receptor signaling | ||||
Reactome | Stimuli-sensing channels | |||
Antigen processing: Ubiquitination & Proteasome degradation | ||||
WikiPathways | TGF beta Signaling Pathway | |||
Signaling by ERBB4 | ||||
Iron uptake and transport |
References | Top | |||
---|---|---|---|---|
REF 1 | US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.